Risk factors for Clostridium difficile toxin-positive nosocomial diarrhoea

被引:51
作者
Raveh, David
Rabinowitz, Bella
Breuer, Gabriel S.
Rudensky, Bernard
Yinnon, Amos M.
机构
[1] Shaare Zedek Med Ctr, Infect Dis Unit, IL-91031 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Jerusalem, Israel
[3] Shaare Zedek Med Ctr, Dept Med, IL-91031 Jerusalem, Israel
[4] Shaare Zedek Med Ctr, Clin Microbiol Lab, IL-91031 Jerusalem, Israel
[5] Hebrew Univ Jerusalem, Fac Med, Sch Med, Jerusalem, Israel
关键词
diarrhoea; Clostridium difficile; antibiotic-associated colitis; pseudomembranous colitis; nosocomial infections;
D O I
10.1016/j.ijantimicag.2006.04.013
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Data were retrieved from the records of all patients from whom stool was sent for Clostridium difficile toxin testing during the year 2001. Toxin-positive and -negative patients were compared by bivariate analysis and regression models. Eight hundred samples from 610 patients were sent for C. difficile toxin testing. Charts of 535 patients (88%) were available for analysis. Of those, 17% had a positive toxin test whilst 83% had a negative toxin test. There was no difference in the number of daily bowel movements between the two groups. Toxin-positive patients were older (P < 0.0001), more often came from nursing homes (P < 0.05), had higher leukocyte counts (P < 0.001), higher blood urea nitrogen (P < 0.01), lower serum albumin (P < 0.01) and more often received diuretics (P < 0.01) and clindamycin (P < 0.05). Logistic regression analysis showed that previous antibiotic-associated diarrhoea was the most significant risk factor for toxin-positive diarrhoea (P < 0.001), followed by clindamycin treatment (P < 0.005), diuretics (P < 0.005) and older age (P < 0.05). Another logistic model showed the contribution of macrolides (P < 0.05) to the development of hospital-acquired diarrhoea. (c) 2006 Published by Elsevier B.V. and the International Society of Chemotherapy.
引用
收藏
页码:231 / 237
页数:7
相关论文
共 25 条
  • [1] CLOSTRIDIUM-DIFFICILE INFECTION ASSOCIATED WITH ANTINEOPLASTIC CHEMOTHERAPY - A REVIEW
    ANAND, A
    GLATT, AE
    [J]. CLINICAL INFECTIOUS DISEASES, 1993, 17 (01) : 109 - 113
  • [2] Clostridium difficile infection among health care workers receiving antibiotic therapy
    Arfons, L
    Ray, AJ
    Donskey, CJ
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 40 (09) : 1384 - 1385
  • [3] Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model
    Baines, SD
    Freeman, J
    Wilcox, MH
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (06) : 974 - 982
  • [4] Clinical manifestations, treatment and control of infections caused by Clostridium difficile
    Bouza, E
    Muñoz, P
    Alonso, R
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2005, 11 : 57 - 64
  • [5] Bulusu M, 2000, AM J GASTROENTEROL, V95, P3137, DOI 10.1111/j.1572-0241.2000.03284.x
  • [6] The role of physical proximity in nosocomial diarrhea
    Chang, VT
    Nelson, K
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 31 (03) : 717 - 722
  • [7] Outbreak of Clostridium difficile infection in a long-term care facility:: Association with gatifloxacin use
    Gaynes, R
    Rimland, D
    Killum, E
    Lowery, HK
    Johnson, TM
    Killgore, G
    Tenover, FC
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 (05) : 640 - 645
  • [8] GROSS MH, 1985, CLIN PHARMACY, V4, P304
  • [9] Mechanisms and management of antibiotic-associated diarrhea
    Högenauer, C
    Hammer, HF
    Krejs, GJ
    Reisinger, EC
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 27 (04) : 702 - 710
  • [10] Comparison of four laboratory tests for diagnosis of Clostridium difficile-associated diarrhea
    Jacobs, J
    Rudensky, B
    Dresner, J
    Berman, A
    Sonnenblick, M
    vanDijk, Y
    Yinnon, AM
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1996, 15 (07) : 561 - 566